1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Intractable Disease Committee Emphasizes Practical Research Fields

A plan to advance the research of intractable diseases in Japan was revealed by Health Science Council’s Subcommittee For Intractable Disease Control And Prevention at the Ministry of Health, Labor and Welfare Nov. 15.

A plan to advance the research of intractable diseases in Japan was revealed by Health Science Council’s Subcommittee For Intractable Disease Control And Prevention at the Ministry of Health, Labor and Welfare Nov. 15. The plan includes creation of a framework for new research fields that correspond to different levels of research such as diagnosis criteria and clinical policies, drug and treatment development, and genome analysis and epidemiological studies. In addition, the plan contains policies concerning assistance given for the development of orphan drugs and information on support for companies in an effort to promote intractable disease drug development. (Click Here For More – Japanese Language

)

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Japan

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

J&J Sets Sights On Robust Japan Growth While Tightening Focus

 
• By Lisa Takagi

Setting its focus on oncology, immunology and rare diseases, the firm anticipates double-digit growth for 2030.

Japan H1 Roundup: Pipeline Shifts Bring Mixed Results

 
• By Lisa Takagi

While Astellas and Daiichi Sankyo rang in double-digit growth, Eisai offset LOE impact with Leqembi’s performance. Takeda struggled with negative results but announced several growth initiatives.

Japanese Bioclusters Aim To Build Communities For Global Success

 
• By Lisa Takagi

Japan's leading bioclusters tell a session at BioJapan that building a tight-knit community will help better connect different players in the startup ecosystem and help ventures grow and expand internationally.

More from Focus On Asia

Hanmi Secures North America Beachhead Via Aptose Acquisition

 
• By Jung Won Shin

Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.

Asia Deal Watch: GSK To Collaborate With LTZ On Myeloid Cell Engagers

 
• By Joseph Haas, Xu Hu, Lisa Takagi, Jung Won Shin, and Sushmita Panda

Plus deals involving Adagene/Third Arc, Celltrion/TRiOar, Celltrion/Kaigene, ImmunoScape/Cue, Laekna/Qilu, Lilly/ABL, Lilly/Sanegene, Sanyou/ZJ Bio-Tech, TransThera/Neurocrine, Qyuns/Roche, Otsuka/4D Molecular, IASO/GC Cell, Chugai/Renalys, Henlius/Forlong and Teijin/Elevara.

Biokin/BMS’s Iza-bren Hits First Phase III OS Endpoint, Albeit In China

 
• By Dexter Jie Yan

Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.